Ticagrelor NICE guidance: Difference between revisions
New page: Normal 0 false false false EN-US X-NONE X-NONE MicrosoftInternetExplorer4 ... |
m Protected "Ticagrelor NICE guidance": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite)) |
||
| (2 intermediate revisions by one other user not shown) | |||
| Line 1: | Line 1: | ||
{{CMG}} | |||
The NICE guidance regarding the utilzation of Ticagrelor is as follows | The NICE guidance regarding the utilzation of Ticagrelor is as follows: | ||
"1.1 Ticagrelor in combination with aspirin is recommended as a treatment option in adults with acute coronary syndromes (ACS) that is, people with: | |||
ST-segment-elevation myocardial infarction (STEMI) - defined as ST elevation or new [[left bundle branch block]] on electrocardiogram - that cardiologists intend to treat with primary percutaneous coronary intervention (PCI) or | |||
non-ST-segment-elevation myocardial infarction (NSTEMI) or | |||
unstable angina - defined as ST or T wave changes on electrocardiogram suggestive of ischaemia and one risk factor for cardiovascular disease (see section 1.2)- in hospitalised patients. After treatment is initiated it should only be continued if the diagnosis is confirmed by a cardiologist. | |||
" | 1.2 For the purposes of this guidance risk factors for cardiovascular disease are: age 60 years or older; previous myocardial infarction; previous coronary artery bypass grafting (CABG); coronary artery disease with stenosis of 50% or more in at least two vessels; previous ischaemic stroke; previous transient ischaemic attack; previous carotid stenosis of at least 50%; previous cerebral revascularisation; diabetes mellitus; peripheral arterial disease; or chronic renal dysfunction, defined as a creatinine clearance of less than 60 ml per minute per 1.73 m2 of body-surface area." | ||
==Sources== | ==Sources== | ||
Latest revision as of 18:21, 27 September 2011
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
The NICE guidance regarding the utilzation of Ticagrelor is as follows:
"1.1 Ticagrelor in combination with aspirin is recommended as a treatment option in adults with acute coronary syndromes (ACS) that is, people with:
ST-segment-elevation myocardial infarction (STEMI) - defined as ST elevation or new left bundle branch block on electrocardiogram - that cardiologists intend to treat with primary percutaneous coronary intervention (PCI) or non-ST-segment-elevation myocardial infarction (NSTEMI) or unstable angina - defined as ST or T wave changes on electrocardiogram suggestive of ischaemia and one risk factor for cardiovascular disease (see section 1.2)- in hospitalised patients. After treatment is initiated it should only be continued if the diagnosis is confirmed by a cardiologist.
1.2 For the purposes of this guidance risk factors for cardiovascular disease are: age 60 years or older; previous myocardial infarction; previous coronary artery bypass grafting (CABG); coronary artery disease with stenosis of 50% or more in at least two vessels; previous ischaemic stroke; previous transient ischaemic attack; previous carotid stenosis of at least 50%; previous cerebral revascularisation; diabetes mellitus; peripheral arterial disease; or chronic renal dysfunction, defined as a creatinine clearance of less than 60 ml per minute per 1.73 m2 of body-surface area."